BR0204767A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR0204767A
BR0204767A BR0204767-5A BR0204767A BR0204767A BR 0204767 A BR0204767 A BR 0204767A BR 0204767 A BR0204767 A BR 0204767A BR 0204767 A BR0204767 A BR 0204767A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition
cefuroxime
lipid
mask
Prior art date
Application number
BR0204767-5A
Other languages
English (en)
Inventor
Matilde Iba Ez Fernandez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0204767A publication Critical patent/BR0204767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA". Trata-se de uma composição compreendendo cefuroxima axetila em forma particulada, as partículas sendo revestidas com revestimentos integrais de lipídio ou de uma mistura de lipídios os quais são insolúveis em água onde a composição adicionalmente compreende um sistema adoçante e um modificador de textura os quais servem para mascarar o sabor amargo da cefuroxima axetila por ocasião de uma administração oral, é revelada.
BR0204767-5A 2001-11-23 2002-11-21 Composição farmacêutica BR0204767A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (1)

Publication Number Publication Date
BR0204767A true BR0204767A (pt) 2003-09-16

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204767-5A BR0204767A (pt) 2001-11-23 2002-11-21 Composição farmacêutica

Country Status (34)

Country Link
US (1) US20030161888A1 (pt)
EP (1) EP1446126B1 (pt)
JP (1) JP3497503B2 (pt)
KR (1) KR100979328B1 (pt)
CN (1) CN1297274C (pt)
AT (1) ATE473006T1 (pt)
AU (2) AU2002302147B2 (pt)
BE (2) BE1015217A5 (pt)
BR (1) BR0204767A (pt)
CA (1) CA2408198C (pt)
CH (1) CH693982A5 (pt)
CO (1) CO5580783A2 (pt)
CY (1) CY1110778T1 (pt)
CZ (1) CZ12993U1 (pt)
DE (3) DE60236952D1 (pt)
DK (1) DK1446126T3 (pt)
ES (2) ES2201932B2 (pt)
FR (1) FR2832635B1 (pt)
GB (1) GB2383536B (pt)
GR (1) GR1004522B (pt)
HR (2) HRP20020924A2 (pt)
HU (1) HUP0204026A3 (pt)
IL (2) IL161972A0 (pt)
IT (1) ITMI20022470A1 (pt)
MX (1) MXPA02011561A (pt)
NO (1) NO335273B1 (pt)
NZ (1) NZ533092A (pt)
PL (1) PL205325B1 (pt)
PT (1) PT1446126E (pt)
RU (1) RU2241460C2 (pt)
SI (1) SI1446126T1 (pt)
TR (1) TR200202559A2 (pt)
WO (1) WO2003043638A1 (pt)
ZA (1) ZA200209473B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011139254A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
WO2013066616A1 (en) 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Pazopanib formulation
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
AU5681294A (en) * 1992-11-30 1994-06-22 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
ES2565163T3 (es) * 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
AU2002302147B2 (en) 2005-01-20
DE20218068U1 (de) 2003-03-27
PL205325B1 (pl) 2010-04-30
RU2241460C2 (ru) 2004-12-10
JP3497503B2 (ja) 2004-02-16
CH693982A5 (de) 2004-05-28
HUP0204026A2 (hu) 2003-08-28
BE1014078A6 (fr) 2003-03-04
EP1446126A1 (en) 2004-08-18
JP2003160493A (ja) 2003-06-03
CO5580783A2 (es) 2005-11-30
IL161972A (en) 2009-06-15
AU2002338950A1 (en) 2003-06-10
HRP20020924A2 (en) 2003-10-31
CA2408198A1 (en) 2003-02-02
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CY1110778T1 (el) 2015-06-10
ATE473006T1 (de) 2010-07-15
GB0227215D0 (en) 2002-12-24
GB2383536A (en) 2003-07-02
NZ533092A (en) 2006-02-24
NO20042620L (no) 2004-06-22
PL357259A1 (en) 2003-06-02
GR1004522B (el) 2004-04-06
CA2408198C (en) 2004-03-09
PT1446126E (pt) 2010-09-24
ITMI20022470A1 (it) 2003-05-24
DE10254412A1 (de) 2003-06-12
KR100979328B1 (ko) 2010-08-31
US20030161888A1 (en) 2003-08-28
WO2003043638A1 (en) 2003-05-30
ES2201932B2 (es) 2005-03-16
EP1446126B1 (en) 2010-07-07
KR20050044590A (ko) 2005-05-12
IL161972A0 (en) 2005-11-20
HU0204026D0 (en) 2003-01-28
MXPA02011561A (es) 2005-07-13
SI1446126T1 (sl) 2010-10-29
BE1015217A5 (pt) 2004-11-09
NO335273B1 (no) 2014-11-03
HRP20020923A2 (en) 2003-10-31
ES2347536T3 (es) 2010-11-02
TR200202559A2 (tr) 2003-06-23
FR2832635A1 (fr) 2003-05-30
CN1297274C (zh) 2007-01-31
DE60236952D1 (de) 2010-08-19
GR20020100506A (el) 2003-07-16
ZA200209473B (en) 2003-06-10
GB2383536B (en) 2003-11-19
ES2201932A1 (es) 2004-03-16
HUP0204026A3 (en) 2004-09-28
FR2832635B1 (fr) 2006-04-21
DK1446126T3 (da) 2010-10-11

Similar Documents

Publication Publication Date Title
BR0204767A (pt) Composição farmacêutica
NO20015782L (no) Kostblanding eller farmasöytisk sammensetning til anvendelse for forebyggelse eller behandling av hyperoksaluri
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
DE602005020796D1 (de) Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
BR0206689A (pt) Combinação de probióticos, e, uso desta
BR9901782A (pt) Forma para dosagem de nefazodona.
GEP20063818B (en) Orodispersible pharmaceutical composition comprising agomelatine
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0400850A2 (hu) Orálisan adagolható gyógyászati készítmények
HUP0201631A2 (hu) Alkalikus szfingomielinázt tartalmazó dietetikus készítmények, ételkiegészítők és gyógyászati termékek
HUP0302441A2 (hu) Antibiotikus hatású gyógyászati készítmények
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
AU2003256157A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
HUP0201629A2 (hu) Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása
TR200200224T2 (tr) Böbrek bozukluğu ve hastalıklarının önlenmesi ve tedavisi için bileşim
EA200600173A1 (ru) Диспергируемая во рту фармацевтическая композиция антитромботического соединения
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
WO2004110470A3 (en) Use of collagen peptides to inhibit infection
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk
BR0306869A (pt) Composição farmacêutica orodispersìvel de piribedila
HUP0103649A3 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues and their use
BR9804052A (pt) Suspensão oral de praziquantel.
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014.